Trial Profile
Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Early breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms Nabrax
- 03 Jun 2014 Final efficacy and biomarker results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 03 Jun 2014 Primary endpoint 'Objective-clinical-response-rate' has not been met.
- 24 May 2014 Status changed from active, no longer recruiting to completed.